Oireachtas Written Answer on Vaccine Cost-Effectiveness for Recombinant Zoster Vaccine (oireachtas.ie)

• Department of Health written response to Oireachtas question
• Cost-effectiveness of recombinant zoster vaccine (Shingrix) under review
• HIQA and NCPE conducting assessments
• HSE Drugs Group to decide on reimbursement

"The Irish Department of Health responded to a parliamentary question on the cost-effectiveness of the recombinant zoster vaccine (Shingrix). The response outlines that evaluations by HIQA and the NCPE will inform future reimbursement decisions by the HSE Drugs Group, potentially impacting vaccine availability in Ireland's public health system."